Autolus Therapeutics, which is developing cancer therapies based on CAR-T cell technology, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The London, United Kingdom-based company was founded in 2014 and booked $2 million in sales for the 12 months ended September 30, 2017. It plans to list on the Nasdaq under the symbol AUTL. Autolus Therapeutics filed confidentially on February 9, 2018. Goldman Sachs and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
